Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Report Date: August 6, 2026
Reporting Period: Fiscal quarter ended June 30, 2026
Context: The filing serves to announce financial results for the specified period via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document referencing a press release (Exhibit 99.1) for detailed data. The filing text itself does not provide specific values for the following metrics:
- Revenue: Not stated in filing text.
- Profit/Loss: Not stated in filing text.
- Cash Flow: Not stated in filing text.
- Margins: Not stated in filing text.
- Debt and Liquidity: Not stated in filing text.
Material Changes
The filing text does not contain comparative data or specific details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release by reference but does not include the text of management commentary, guidance, or outlook within the 8-K body.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: No unusual items are described in the filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the company has issued any forward-looking guidance for the remainder of fiscal 2026.